{"analyses":[{"ciLowerLimit":"0.73","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.30","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.440","paramType":"Hazard Ratio (HR)","paramValue":"0.98","statisticalComment":"One-sided p-value from stratified log-rank test were adjusted for previous treatment with anti-CD38, ISS staging and number of prior lines of therapy.","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.4","upperLimit":"33.2","value":"24.0"},{"groupId":"OG001","lowerLimit":"16.0","upperLimit":"29.3","value":"22.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"218"},{"groupId":"OG001","value":"107"}],"units":"Participants"}],"description":"OS is defined as the time from randomization until death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with relapsed/refractory multiple myeloma (RRMM) received 30 minutes intravenous infusion of 2.5 milligram/kilogram (mg/kg) belantamab mafodotin on day 1 of each 21-day cycle","id":"OG000","title":"Belantamab Mafodotin"},{"description":"Participants with RRMM received 4 mg pomalidomide capsule daily on Days 1 to 21 of each 28-day cycle, along with 40 mg or at lower 20 mg (for participants \\>75 years of age) dose of dexamethasone tablet once weekly (Days 1, 8, 15 and 22)","id":"OG001","title":"Pomalidomide Plus Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"ITT Population","reportingStatus":"POSTED","timeFrame":"Up to approximately 263 weeks","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}